Memorial Sloan Kettering Cancer Center, founded in 1884, unites specialized care teams across more than 400 cancer subtypes with a research enterprise anchored by more than 120 laboratories and 38 core facilities. In the 2026-27 U.S. News & World Report “Best Hospitals” rankings, MSK placed No. 2 nationally for cancer care, while also ranking No. 1 in the Northeast and New York metropolitan area for cancer and No. 1 nationally for urology. In 2025, MSK’s 514 inpatient beds and 72,000-square-foot surgical center supported 1,435 attending physicians and 4,691 nurses across 25,690 admissions and 1,079,254 outpatient visits. MSK’s surgeons perform more cancer operations than physicians at any other U.S. hospital, its radiation oncologists pioneered intensity-modulated radiation therapy and now also offer proton therapy, and its research has produced 11 FDA-approved drugs to date, a success rate unmatched by any other cancer center. The Sloan Kettering Institute, the cancer center’s basic research arm, works across eight major research programs alongside a faculty that includes 27 members of the National Academy of Medicine, 14 members of the National Academy of Sciences and eight Howard Hughes Medical Institute investigators. The cancer center trained 2,191 residents and clinical fellows, 551 postdoctoral fellows and research scholars, 379 PhD and MD/PhD candidates, 426 nursing students and 532 medical students in 2025, through partnerships that include an MD/PhD program with Weill Cornell Medical College and The Rockefeller University. The center holds accreditation from the Commission on Cancer, the Joint Commission and the American Nurses Credentialing Center’s Magnet recognition program.
